Newsletter Subject

Undefined, Last Call To Receive Rare TWK Bonus Picks

From

biotechbreakouts.com

Email Address

kyle@biotechbreakouts.com

Sent On

Mon, Oct 12, 2020 12:57 AM

Email Preheader Text

Dear Undefined, It’s the last call, your window of opportunity at midnight. On Monday I will re

Dear Undefined, It’s the last call, your window of opportunity at midnight. [Your exclusive opportunity to join Trade With Kyle for $299 and receive my 3 highest-conviction picks disappears.]( On Monday I will release the first of my three bonus picks... However, it looks like you’ll be on the sidelines. Potentially missing out on three of the hottest biotech stocks of 2020. As well as… [this RARE OPPORTUNITY to gain quarterly access to Trade With Kyle for $299.]( After midnight, prices for Trade With Kyle return back to normal… You’ll only be able to gain access to the service at either $1497 for annual or $2497 for platinum. Do you really want to pay more when you don’t have to? Listen, I’ve made more than $4M in 2020*. A bulk of those gains came from trading biotech catalysts. If you want to tap into my mind and really dissect how millionaire traders think and move in this market… [Then subscribing to Trade With Kyle is an absolute must.]( I want to show you how to take advantage of the perfect storm of opportunities in biotechs. I believe Trade With Kyle puts you in a position to do that. However, I can’t click the subscribe button for you. That’s all on you. [It’s time to make a move.]( [The clock is moving against you.]( [Don’t let this opportunity slip by.]( Kyle Dennis RagingBull, LLC 62 Calef Hwy. #233, Lee, NH 03861 [Click Here to stop receiving emails from kyle@biotechbreakouts.com]( [Unsubscribe from all RagingBull emails]( DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website,application or other service ("Services"), please review our full disclaimer located at [(disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT beconstrued as a securities-related offer or solicitation, or be relied upon as personalizedinvestment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securitiesregulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services. However, Ragingbull.com, LLC, its owners, and itsemployees may purchase, sell, or hold long or short positions in securities of the companies mentioned inthis communication. If you have a current active subscription with Biotech Breakouts you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at BiotechBreakouts.com.

Marketing emails from biotechbreakouts.com

View More
Sent On

31/07/2021

Sent On

31/07/2021

Sent On

17/07/2021

Sent On

09/07/2021

Sent On

08/07/2021

Sent On

08/07/2021

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.